A common supplement may shield bones in kidney disease — a trial puts it to the test

NCT ID NCT05918029

Terminated Disease control Sponsor: Albert Einstein College of Medicine Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This pilot trial investigates whether potassium citrate can improve bone quality and strength in adults and children with chronic kidney disease. Participants take either potassium citrate or a placebo for six months, along with blood and urine tests and advanced bone scans. The goal is to see if this simple supplement can help prevent bone loss in this vulnerable population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: potassium citrate (extended-release tablet or oral solution)
What this could lead to: If it works, this could point toward a simple supplement to protect bones in people with chronic kidney disease.
What could go wrong: This is a very small pilot trial with only 6 participants, so results may not apply broadly. Potassium citrate can cause stomach upset or high potassium levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acidosis Bone Diseases, Metabolic bone fracture chronic kidney disease chronic renal failure syndrome osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE LOSS CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

Albert Einstein College of Medicine

The Bronx, New York, 10461, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.